Advertisement

Topics

Results show promise for PARP-inhibitor combination therapy in prostate cancer

03:10 EDT 12 Jun 2018 | EPM Magazine

Data has been presented by AstraZeneca and Merck demonstrating clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a standard of care

Original Article: Results show promise for PARP-inhibitor combination therapy in prostate cancer

NEXT ARTICLE

More From BioPortfolio on "Results show promise for PARP-inhibitor combination therapy in prostate cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...